Oropharyngeal carcinoma State of the Art
|
|
- Arlene Eaton
- 8 years ago
- Views:
Transcription
1 Oropharyngeal carcinoma State of the Art Pr. Jean Bourhis Institute Gustave Roussy Ville juif, France - Among HNSCC what are the specificities of the oropharyngeal sub site? - Frequent among HNSCC - More HPV related carcinomas (up to 5-75%) - Importance of IMRT for parotid sparing - Are the results obtained in the orophaynx different from the rest of HNSCC? - Relative consensus on «general treatment guidelines» Multidisciplinary approach in oropharynx carcinomas T1-T2 T3-T4* Surgery (IM)RT (Uvula-tonsil) Surgery Inoperable (brachy) or non infiltrating (IM)RT-CT or HPV) (IM)RT-erbitux Post-op RT +/- CDDP * induction chemo revisited 1
2 How different are the oropharyngeal carcinomas as compared to the other HNSCC? How different are the oropharyngeal carcinomas as compared to the other HNSCC? For altered fractionation Is the effect of altered fractionated RT any different in oropharynx sub site? MARCH database of randomized trials ( ) Hyperfractionated or accelerated RT Conventional RT 2
3 MACH-NC Meta-Analysis of Chemotherapy in 1 Head & Neck Cancer Overall results (all sites) Loco regional control 1 Risk of recurrence (%) Hyperfractionation 57.9% 48.5% Risk of recurrence (%) Acceleration w / o total dose reduction 47.5% 4.2% Time from randomisation (Years) Time from randomisation (Years) 1 Alt. fractionated RT Conventional RT Risk of recurrence (%) IGR, June % 57.5% Time from randomisation (Years) Acceleration with total dose reduction 7 Risk of recurrence (%) 8 Absolute difference at 5 years: 6.4 ± 1.3% % % 2 All the 3 groups together Time from randomisation (Years) Altered fractionated RT database (N > 65 patients randomized) Characteristics Altered fractionated RT (n=3,65) Conventional RT (n=3,423) Site of tumour - Oral cavity 13% 13% - Oropharynx 44% 44% - Larynx 34% 33% - Hypopharynx 8% 8% - Others 2% 2% Stage - I 9% 9% - II 18% 16% - III 28% 29% - IV 46% 45% Altered fractionated versus conventional RT : survival by site Category No. Deaths / No. Entered Alt. fractionated RT Control O-E Variance Hazard Ratio Interaction test Age 5 or less 374/68 394/ / / / / or over 48/ / Sex Male 1916/ / Female 388/63 387/ p =.2 p =.39 Performance status 117/ / /1348 9/ or 3 297/ / Stage I-II 397/95 355/ III 639/ / p =.23 p =.1 IV 1265/ / Site Oral 282/37 278/ cavity Oropharynx 115/ / Larynx 586/ / p =.2 Hypopharynx 235/ / Others 52/69 45/ fractionated better Control better Alt. RT 3
4 MARCH: Overall survival by age (incl. oropharynx) Hazard ratio Category No. Events / No. Entered (Alt. fractionated RT/Control) HR [95% CI] 5 or less 768 / / / / [ ].95 [ ].92 [ ] 1.8 [ ] Total / [ ] Test of interaction: p = Alt. Frac. RT better Control better Test for trend: p =.7 Alt. fractionated RT effect p=.2 How different are the oropharyngeal carcinomas as compared to the other HNSCC? For Chemo-RT A few pure oropharynx randomized trials 4
5 Example of specific trial : RT-CT 94-1 trial 7 Gy / 7 weeks N = 226 T3-T4 oropharynx Non operated 7 Gy / 7 weeks + Carbo-5FU 1 GORTEC 94-1 : oropharynx 9 8 LR 7 control rate (%) % 4 LOCO-REGIONAL CONTROL p =,2 > concomitant t RT - CT 25% 3 2 > RT alone 1 months after randomization GORTEC 94-1 : oropharynx 8 7 Overall 6 survival rate (%) 5 OVERALL SURVIVAL 7% % 2 16% 1 > RT / CT > RT months after randomization p (Mantel-Cox Logrank) =,6 5
6 Concomitant chemo : the price to pay? GORTEC 94-1 : oropharynx : Acute toxicity RT RT+CT P value Mucositis Patchy Confluent 7 14 Skin Erythema. Dry desquamation Moist desquamation Nutritional status Weight loss >1% of body mass Feeding tube Haematology Neutrophils < Platelets < Hemoglobin < 8 g/1ml 3.5 Toxic death 1 GORTEC 94-1 : oropharynx : Late toxicity 6
7 Is the effect of adding chemotherapy to RT any different in oropharynx sub site? MACH-NC database of randomized trials (1965-2) RT-CT RT MACH-NC Meta-Analysis of Chemotherapy in Head & Neck Cancer PERCENT 19 Chemotherapy data base ( N=9615 pts randomized ) Oral cav. Orop. Larynx Hypop. Others Site of Primary Treatment: Chemotherapy No Chemotherapy MACH-NC Effect of concomitant CT-RT versus RT (survival by site) Meta-Analysis of Chemotherapy in Head & Neck Cancer 17% % % % + 6-3%
8 MACH-NC Meta-Analysis of Chemotherapy in Head & Neck Cancer Chemotherapy is more beneficial in younger patients (N = 9615 pts randomized) Age Absolute survival benefit at 5 years < 5 12% % p< % > % IGR, June 24 MACH-NC Meta-Analysis of Chemotherapy in Head & Neck Cancer Platin-5FU : concomitant versus induction 1 Chemotherapy Control 8 of recurrence (%) Risk o Local failure 63.2 % 49.7 % Distant failure 18.9 % 16 % Time from randomisation (Years) of recurrence (%) 1 Chemotherapy Control 8 Local failure % 49.1 % 4 Risk o Distant failure % 12.1 % Time from randomisation (Years) Concomitant Absolute difference at 5 years: Local failure: ± 2.8 % Distant failure: -2.9 ± 2.7% Neoadjuvant Absolute difference at 5 years: Local failure: 1.8 ± 2.3 % Distant failure: -3.5 ± 2. % MACH-NC Meta-Analysis of Chemotherapy in Head & Neck Cancer Concomitant PF > induction PF ; but TPF > PF 1 Chemotherapy Control 8 of recurrence (%) Risk o Local failure 63.2 % 49.7 % Distant failure 18.9 % 16 % Time from randomisation (Years) of recurrence (%) 1 Chemotherapy Control 8 Local failure % 49.1 % 4 Risk o Distant failure 2 Taxotere-PF 15.6 % versus PF, Vermorken % Time from randomisation (Years) Concomitant Absolute difference at 5 years: Local failure: ± 2.8 % Distant failure: -2.9 ± 2.7% Neoadjuvant Absolute difference at 5 years: Local failure: 1.8 ± 2.3 % Distant failure: -3.5 ± 2. % 8
9 TAX324 : Survival Log-Rank P =.5 Hazard Ratio =.7 Survival Probability (%) TPF PF 2 1 TPF (n=255) PF (n=246) Survival Time (months) Number of patients at risk TPF: PF: Posner M, et al. N Engl J Med 27;357: MACH-NC Meta-Analysis of Chemotherapy in Head & Neck Cancer 1 of recurrence (%) Risk o Chemotherapy Control TPF : a new standard for induction CT in HNSCC Local failure 63.2 % 49.7 % Distant failure 18.9 % 16 % Time from randomisation (Years) of recurrence (%) Risk o Chemotherapy Control TPF TPF Local failure 5.9 % 49.1 % 15.6 % Distant failure 12.1 % Time from randomisation (Years) Concomitant Absolute difference at 5 years: Local failure: ± 2.8 % Distant failure: -2.9 ± 2.7% Neoadjuvant Absolute difference at 5 years: Local failure: 1.8 ± 2.3 % Distant failure: -3.5 ± 2. % With no significant difference in toxicity MACH-NC Meta-Analysis of Chemotherapy in Head & Neck Cancer Combining TPF induction + concomitant? 1 Chemotherapy Control 1 Chemotherapy Control 8 Local failure % 6 Local failure 6 TPF 5.9 % 49.7 % % 4 Distant failure? TPF Distant failure 18.9 % % 16 % 12.1 % Time from randomisation (Years) Time from randomisation (Years) of recurrence (%) Risk o of recurrence (%) Risk o Concomitant Absolute difference at 5 years: Local failure: ± 2.8 % Distant failure: -2.9 ± 2.7% Efficacy? / toxicity? Neoadjuvant Absolute difference at 5 years: Local failure: 1.8 ± 2.3 % Distant failure: -3.5 ± 2. % 9
10 How different are the oropharyngeal carcinomas as compared to the other HNSCC? For erbitux Erbitux + Radiotherapy : a good ratio efficacy / toxicity in locally advanced HNSCC ERBITUX + RT in locally advanced HNSCC : a phase III randomized study (the most important sub site was oropharyngeal cancer) stage III and IV non metastatic HNSCC R RT (n=213) ERBITUX + RT (n=211) Primary endpoint: Locoregional control Bonner J, et al. N Eng J Med 26;354:
11 RT + cetuximab : local-regional control (more effect was seen in oropharynx (subgroup?) P =.2 31 ival probability Survi Benefit also found with Erbitux + chemo in relapse / metastatic patients : Extreme randomized study :.4.3 Cetuximab + CTX.2.1 Log-rank : p =.3 CTX only Patients at risk Survival time (months) Vermorken JB, et al. ASCO 27 (Abstract No. 691; updated information presented) Oropharyngeal carcinomas : Importance of IMRT 11
12 IMRT, intensity modulated RT IMRT in Oropharyngeal carcinoma 1) Better normal tissue protection (parotid) 2) Dose escalation to the tumor Potentially Interesting since : - Most relapses in the GTV - Dose effect relationship IMRT : increased dose conformality clinical benefit? IMRT in oropharynx carcinomas : carcinological results Mendenhall W. JCO 26 12
13 IMRT in oropharyngeal carcinomas : a multicentric prospective study of patients necessitating a bilateral IMRT (M Lapeyre) GORTEC : Loco-regional & survival (N= 93) 1,75,5 Contrôle loco-régional,25 Survie globale Recul moyen : 14 mois (3-37) Late xerostomia (N =93) (RTOG-EORTC scoring system) 1,,8,6,4 grade -1 grade 2-3,2, 3 mois 6 mois 12 mois 18 mois 13
14 Salivary toxcity at 1 year Grade 2-3 Controlateral lparotid : Dose moy < 3 Gy Dose moy > 3 Gy 16 % 43 % p=,5 QOL : 7 scores in favor of IMRT Scoring of symptoms Dolor (HN) Deglutition Eating in public Dental Pbs Opening mouth Mouth dryness Stick saliva RTE conv IMRT p 33,5 [28,5] 35,1 [26,2] 38,2 [31,8] 34,9 [4,] 48,3 [37,7] 83,1 [25,5] 76,6 [3,1] 21,5 [25,] 23, [25,6] 26,9 [3,3] 19,5 [3,6] 28,8 [31,9] 57,2 [33,2] 47,1 [34,7],1,1,3,2,1 <,1 <,1 Graff P et al Int J Radiat Oncol Biol Phys. 27 Apr 1;67(5): Dose escalation with IMRT in oropharyngeal carcinomas? An ongoing randomized study with / wo IMRT (GORTEC 24-1) Oropharynx + OC Stage II-IV with R 7 Gy + CDDP IMRT 75 Gy + CDDP Hypothesis = IMRT 75 Gy more efficient & less toxic? N = 67 pts 14
15 IMRT in oropharynx carcinomas : summary - Better conformality / 3D, & one of the tumor sites where it is increasingly used Steep dose gradient : need for clinical validation in locally advanced ddisease - Promizing & converging results (EBM 2-3) : - Few LR recurrence - Less late toxicity - Learning curve / Re-inforced QA needed ++ Radiotherapy for oropharyngeal carcinoma : Importance of the RT-QA Radiotherapy for oropharyngeal carcinoma : Importance of the RT-QA contouring 15
16 Importance of RT-QA : contouring ; international survey : T2 Tonsil Primary Tumor Neck Node Harari 24 Samples : Elective CTV Designs Harari 24 Radiotherapy for oropharyngeal carcinomas : Importance of the RT-QA RT plan verification 16
17 LR Failure according to RT plan deviations yes / no (N= 82) (Rishin, ASCO 28) 1 nal failure-free Estimated percentage locoregio P <.1 compliant plan by TMC no adv impact adv impact No deviation Deviation Years following end of radiotherapy IMRT : what s next? New tools for radiation delivery : Image guided RT Adaptive RT Dose Guided RT Adaptive Radiotherapy - Anatomic and set-up Changes 19 CT Scans over 47 Days Elapsed Days Patient Immobilized with Acquaplast Mask Barker et al. IJROBP 59:96-97, 24 (MDACC); Lei Dong et al. (MDACC) 17
18 Dose distribution in Superior Constrictor Muscle from Brachytherapy in Tonsillar Fossa (< 5%) mcs Brachytherapy Boost 1% TF Peter Levendag et al EORTC H&N35 Swallowing / Dose swallowing muscles % Probability severe dysphagia MCM MCS Cyberknife boost Dose Constrictor Muscles(Gy) CBK patients EORTC H&N35 Swallowing / Dose swallowing muscles % Probability severe dysphagia MCM MCS Brachytherapy boost Dose Constrictor Muscles(Gy) BT patients Peter Levendag et al New generation of trials in locally advanced oropharyngeal carcinomas? Most of them do integrate concomitant CT-RT (CDDP-RT) 18
19 New generation of trials for oropharynx carcinomas : concomitant CT-RT & modifying the radiotherapy GORTEC 99-2 randomized trial Conventional RT + Carbo/5FU Stage III/IV Accelerated RT + Carbo/5FU Very accelerated RT N = 84 pts randomized, 2/3 of oropharynx GORTEC Progression free survival RTconv-CT Arm A.7 Arm B.6 RTacc-CT.5 Very-Acc-RT Arm C 33.4%.4.3 A vs B vs C p=.7 A vs B p= % 31.7% A vs C p=.3 * At risk Years * Ajusté sur T, N et localisation 19
20 New generation of trials in locally advanced oropharyngeal carcinomas? concomitant CDDP-RT & adding a new drug RTOG H5-22 : Phase III Stage III-IV HNSCC R A N D O M I Z E Accelerated FX CDDP Accelerated FX CDDP Erbitux Future directions : multiple targeting? Example : ZD6474 : a Dual EGFR-VEGFR TKI EGFR TGFα ZD6474 Cancer cell ras MEK VEGF Endothelial cell KDR Cyclin D1 Endothelial cell proliferation Proliferation Wedge SR, et al. Cancer Res 22;62:
21 Multiple- better than single-targeting? several ongoing trials in HNSCC Phase I (Localy advanced HNC) Brizel, 27 RT- CDDP + Erlotinib R RT- CDDP + Avastin RT-CDDP + Erlotinib + Avastin New GORTEC trial (> 2/3 oropharynx) Erbitux - RT R T2-T4 N-N1 Erbitux - RT + Carbo-5FU (best arm 99-2) New generation of trials in localy advanced oropharyngeal carcinomas? concomitant CT-RT & testing induction CT 21
22 6 ongoing randomized trials (Decide, Paradigm, Paccagnella etc ) R RT-CT TPF RT-CT Other Strategy tested : a new GORTEC trial TPF Erbitux - RT R T2-T4 N2b-N3 RT-CT (best arm 99-2) New generation of trials in localy advanced oropharyngeal carcinomas? Replacing CDDP concomitant to RT by a molecular targeted drug (erbitux)? 22
23 Replacing chemo by a molecular targeted drug? larynx preservation randomized trial (GORTEC-GETTEC) TPF CDDP-RT R TPF + Erbitux-RT Decreasing the dose intensity of the treatment : a relevant question for HPV+ oropharyngeal carcinomas? Other directions in oropharyngeal carcinoma specific treatments for HPV related tumors? - HPV found in 2-25% of HNSCC (and 3% benign biopsies of oropharynx) - Up to 5% in oropharynx carcinomas (some series : 9%) : % HPV16 (De Souza, NEJM 27) - HPV+ tumors associated with : - Better survival (Richties 23) - Better survival in surgically treated tumors (Licitra JCO 26) - More radiosensitivity (Lindel 27) - More response to induction chemo (Worden JCO 28) - Cellular marker of prognostic value : p16 (Lassen JCO 29 survival 62% versus 26% with conventional RT) 23
24 Do we need different therapeutic approaches for HPV associated oropharyngeal tumors? - De-escalation? - Value of EGFr targeting instead of concomitant chemo? - Other specific anti-viral strategies? Antiviral agent Cidofovir + irradiation in HPV+ SC carcinoma xenografts (ongoing phase I) HPV+ xenografts 6 Control r volume Fractional tumor Cidofovir IR Cidofovir +IR Days Oropharyngeal carcinoma - Conclusions - - High proportion of HNSCC (about 5%) - The effect of chemotherapy and/or altered fractionation or EGFr targeting = not different from the other HNSCC EBM level 1a - Importance of IMRT / IGRT / RT-QA for normal tissue sparing in this particular sub-site - Question : more HPV related carcinomas (specific targeting? Treatment Desescaltion)? 24
25 25
Concurrent Chemotherapy and Radiotherapy for Head and Neck Cancer
Concurrent Chemotherapy and Radiotherapy for Head and Neck Cancer Ryan J. Burri; Nancy Y. Lee Published: 03/23/2009 Abstract and Introduction Abstract Head and neck cancer is best managed in a multidisciplinary
More informationEvolution of Head and Neck Treatment Using Protons. Mayank Amin, M.Sc,CMD
Evolution of Head and Neck Treatment Using Protons Mayank Amin, M.Sc,CMD Facility Layout Gantry Room 3 Fixed Beams Room 4 HEBT Gantry Room 2 Gantry Room 1 Synchrotron Linac Treatment Planning Imaging Area
More informationImplementation Date: April 2015 Clinical Operations
National Imaging Associates, Inc. Clinical guideline PROSTATE CANCER Original Date: March 2011 Page 1 of 5 Radiation Oncology Last Review Date: March 2015 Guideline Number: NIA_CG_124 Last Revised Date:
More informationSAKK Lung Cancer Group. Current activities and future projects
SAKK Lung Cancer Group Current activities and future projects SAKK Lung Cancer Group Open group of physicians interested in lung cancer Mostly Medical Oncologists, but also Thoracic Surgeons Radiation
More informationSCD Case Study. Most malignant lesions of the tonsil are either lymphosarcoma or carcinoma.
SCD Case Study Dry Mouth This case study details a patient who has experienced xerostomia as a result of treatment for squamous cell carcinoma of the left tonsil involving surgery followed by deep x-ray
More informationLOCALLY ADVANCED SQUAMOUS CARCINOMA OF THE HEAD AND NECK
LOCALLY ADVANCED SQUAMOUS CARCINOMA OF THE HEAD AND NECK Executive Summary The annual incidence of head and neck cancers worldwide is more than 550,000 cases with around 300,000 deaths each year [1]. Male
More informationMultidisciplinary Management of Head and Neck Cancer I
Multidisciplinary Management of Head and Neck Cancer I Min Yao, M.D., Ph.D. Department of Radiation Oncology University Hospitals Case Medical Center Case Western Reserve University Nothing to disclose
More informationCarcinoma of the Cervix. Kathleen M. Schmeler, MD Associate Professor Department of Gynecologic Oncology
Carcinoma of the Cervix Kathleen M. Schmeler, MD Associate Professor Department of Gynecologic Oncology Cervical Cancer Treatment Treatment Microinvasive (Stage IA1): Simple (extrafascial) hysterectomy/cone
More informationApproccio multidisciplinare nei tumori del retto
Approccio multidisciplinare nei tumori del retto F. Muñoz Radiation Oncology Department University of Torino, Italy RECENT CHANGES IN RECTAL CANCER DIAGNOSIS AND THERAPY Optimal staging by EUS and MRI
More informationIntensity Modulated Radiation Therapy (IMRT) for Thyroid Cancer
Thyroid Science 5(1):CLS1-8, 2010 www.thyroidscience.com Clinical and Laboratory Studies Intensity Modulated Radiation Therapy (IMRT) for Thyroid Cancer 1 2 5 Aruna Turaka, MD, Tianyu Li, MS, Jian Q. Yu,
More informationStomach (Gastric) Cancer. Prof. M K Mahajan ACDT & RC Bathinda
Stomach (Gastric) Cancer Prof. M K Mahajan ACDT & RC Bathinda Gastric Cancer Role of Radiation Layers of the Stomach Mucosa Submucosa Muscularis Serosa Stomach and Regional Lymph Nodes Stomach and Regional
More informationPrinciples of Radiation Therapy A Bapsi Chakravarthy, MD Associate e P rofessor Professor Radiation Oncology
Principles of Radiation Therapy A Bapsi Chakravarthy, MD Associate Professor Radiation Oncology Disclosure Information I have no financial relationships to disclose relevant to the conten of this presentation.
More informationThe evolution of rectal cancer therapy. Objectives
The evolution of rectal cancer therapy Hagen Kennecke MD MHA FRCPC Western Canada Consensus Conference September 5, 2014 Objectives Identify standard therapy: stage II/III rectal cancer Update recent adjuvant
More informationHow TARGIT Intra-operative Radiotherapy can help Older Patients with Breast cancer
How TARGIT Intra-operative Radiotherapy can help Older Patients with Breast cancer Jeffrey S Tobias, Jayant S Vaidya, Frederik Wenz and Michael Baum, University College Hospital, London, UK - on behalf
More informationManagement of stage III A-B of NSCLC. Hamed ALHusaini Medical Oncologist
Management of stage III A-B of NSCLC Hamed ALHusaini Medical Oncologist Global incidence, CA cancer J Clin 2011;61:69-90 Stage III NSCLC Includes heterogeneous group of patients with differences in the
More informationManagement of Postmenopausal Women with T1 ER+ Tumors: Options and Tradeoffs. Case Study. Surgery. Lumpectomy and Radiation
Management of Postmenopausal Women with T1 ER+ Tumors: Options and Tradeoffs Michael Alvarado, MD Associate Professor of Surgery University of California San Francisco Case Study 59 yo woman with new palpable
More informationMaintenance therapy in in Metastatic NSCLC. Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai
Maintenance therapy in in Metastatic NSCLC Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai Definition of Maintenance therapy The U.S. National Cancer Institute s
More informationNeoadjuvant chemotherapy or chemoradiotherapy in head and neck cancer
Review Article Neoadjuvant chemotherapy or chemoradiotherapy in head and neck cancer Preetesh Jain, Prabhash Kumar, Vasanth Raghuvir Pai, Purvish Mahendra Parikh Department of Medical Oncology, Tata Memorial
More informationRadiation Therapy for Prostate Cancer: Treatment options and future directions
Radiation Therapy for Prostate Cancer: Treatment options and future directions David Weksberg, M.D., Ph.D. PinnacleHealth Cancer Institute September 12, 2015 Radiation Therapy for Prostate Cancer: Treatment
More informationGuidelines for the treatment of breast cancer with radiotherapy
London Cancer Guidelines for the treatment of breast cancer with radiotherapy March 2013 Review March 2014 Version 1.0 Contents 1. Introduction... 3 2. Indications and dosing schedules... 3 2.1. Ductal
More informationthe standard of care 2009 5/1/2009 Mesothelioma: The standard of care take home messages PILC 2006 Jan.vanmeerbeeck@ugent.be Brussels, March 7, 2009
Mesothelioma: The standard of care Jan.vanmeerbeeck@ugent.be Brussels, March 7, 2009 take home messages PILC 2006 All patients should receive adequate palliation of dyspnea and pain before starting chemotherapy
More informationThe Science behind Proton Beam Therapy
The Science behind Proton Beam Therapy Anthony Zietman MD Shipley Professor of Radiation Oncology Massachusetts General Hospital Harvard Medical School Principles underlying Radiotherapy Radiation related
More informationPancreatic Cancer: FDA Approved Treatments and Clinical Trials
Pancreatic Cancer: FDA Approved Treatments and Clinical Trials Vincent J Picozzi MD MMM Virginia Mason Medical Center Seattle WA 1 Pancreatic cancer is the hardest cancer of all to treat 2 Pancreatic cancer:
More informationRadiation therapy involves using many terms you may have never heard before. Below is a list of words you could hear during your treatment.
Dictionary Radiation therapy involves using many terms you may have never heard before. Below is a list of words you could hear during your treatment. Applicator A device used to hold a radioactive source
More informationClinical Education A comprehensive and specific training program. carry out effective treatments from day one
Proton Therapy Clinical Education A comprehensive and specific training program carry out effective treatments from day one Forewarned is forearmed Although over 100,000 patients have been treated in proton
More informationRadiotherapy in locally advanced & metastatic NSC lung cancer
Radiotherapy in locally advanced & metastatic NSC lung cancer Dr Raj Hegde. MD. FRANZCR Consultant Radiation Oncologist. William Buckland Radiotherapy Centre. Latrobe Regional Hospital. Locally advanced
More information7. Prostate cancer in PSA relapse
7. Prostate cancer in PSA relapse A patient with prostate cancer in PSA relapse is one who, having received a primary treatment with intent to cure, has a raised PSA (prostate-specific antigen) level defined
More informationRadioterapia panencefalica. Umberto Ricardi
Radioterapia panencefalica Umberto Ricardi Background Systemic disease to the brain is unfortunately a quite common event Radiotherapy, especially with the great technical development during the past decades,
More informationLoco-regional Recurrence
Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer AGO AGO e. e. V. V. Loco-regional Recurrence Loco-regional Recurrence Version 2002: Brunnert / Simon Versions 2003 2012: Audretsch
More informationREPORT ASCO 2002 ORLANDO : LUNG CANCER Johan F. Vansteenkiste, MD, PhD, Univ. Hospital and Leuven Lung Cancer Group
REPORT ASCO 2002 ORLANDO : LUNG CANCER Johan F. Vansteenkiste, MD, PhD, Univ. Hospital and Leuven Lung Cancer Group In the 2002 edition of the ASCO meeting, a total of 315 abstracts in the field of respiratory
More informationInterventions for the treatment of oral cavity and oropharyngeal cancer: radiotherapy (Review)
Interventions for the treatment of oral cavity and oropharyngeal cancer: radiotherapy (Review) Glenny AM, Furness S, Worthington HV, Conway DI, Oliver R, Clarkson JE, Macluskey M, Pavitt S, Chan KKW, Brocklehurst
More informationManagement of low grade glioma s: update on recent trials
Management of low grade glioma s: update on recent trials M.J. van den Bent The Brain Tumor Center at Erasmus MC Cancer Center Rotterdam, the Netherlands Low grades Female, born 1976 1 st seizure 2005,
More informationTHE SECRETS OF OUR SUCCESS
THE SECRETS OF OUR SUCCESS QUALITY OF LIFE STUDIES OF THE NCIC Andrea Bezjak, MDCM, MSc,, FRCPC Chair, NCIC CTG QOL Committee Outline of the Presentation Can we consider NCIC CTG QOL activities a success?
More informationTITLE: Comparison of the dosimetric planning of partial breast irradiation with and without the aid of 3D virtual reality simulation (VRS) software.
SAMPLE CLINICAL RESEARCH APPLICATION ABSTRACT: TITLE: Comparison of the dosimetric planning of partial breast irradiation with and without the aid of 3D virtual reality simulation (VRS) software. Hypothesis:
More informationClinical Trials and Radiation Treatment. Gerard Morton Odette Cancer Centre Sunnybrook Research Institute University of Toronto
Clinical Trials and Radiation Treatment Gerard Morton Odette Cancer Centre Sunnybrook Research Institute University of Toronto What I will cover.. A little about radiation treatment The clinical trials
More informationRadiation Therapy in the Treatment of
Lung Cancer Radiation Therapy in the Treatment of Lung Cancer JMAJ 46(12): 537 541, 2003 Kazushige HAYAKAWA Professor and Chairman, Department of Radiology, Kitasato University School of Medicine Abstract:
More informationRadiotherapy in Plasmacytoma and Myeloma. David Cutter Multiple Myeloma NSSG Annual Meeting 14 th September 2015
Radiotherapy in Plasmacytoma and Myeloma David Cutter Multiple Myeloma NSSG Annual Meeting 14 th September 2015 Contents Indications for radiotherapy: Palliation in Multiple Myeloma Solitary Bone Plasmacytoma
More informationCetuximab (Erbitux) MM.04.005 05/10/2005. HMO; PPO; QUEST Integration 01/01/2015 Section: Prescription Drugs Place(s) of Service: Office: Outpatient
Cetuximab (Erbitux) Policy Number: Original Effective Date: MM.04.005 05/10/2005 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 01/01/2015 Section: Prescription Drugs Place(s)
More informationProton Therapy Center Czech
Proton Therapy Center Czech The main goal of radiotherapy is to irreversibly damage tumor cells, whereas the cells of healthy tissue are damaged only reversibly or not at all. Proton therapy currently
More informationNeoadjuvant therapy are we doing it right? Short course and chemoradiation
Neoadjuvant therapy are we doing it right? Short course and chemoradiation Rob Glynne-Jones Mount Vernon Cancer Centre Relevant Endpoints in rectal cancer Local recurrence Disease-free survival Overall
More informationCancer - Therapeutic Process of Rapid proliferating Tumors
Workshop Interdisciplinare radiazioni: biologia, clinica, ambiente e protezione Centro Ricerche Casaccia ENEA Roma, 14 maggio 2009 basse dosi in radioterapia Alessio G. Morganti 1,2,3, Mariangela Massaccesi
More informationProton Therapy for Prostate Cancer
Proton Therapy for Prostate Cancer Andrew K. Lee, MD, MPH Director, Proton Therapy Center Associate Professor Department of Radiation Oncology M.D. Anderson Cancer Center Randomized studies showing benefit
More informationA new score predicting the survival of patients with spinal cord compression from myeloma
A new score predicting the survival of patients with spinal cord compression from myeloma (1) Sarah Douglas, Department of Radiation Oncology, University of Lubeck, Germany; sarah_douglas@gmx.de (2) Steven
More informationTable of Contents. Data Supplement 1: Summary of ASTRO Guideline Statements. Data Supplement 2: Definition of Terms
Definitive and Adjuvant Radiotherapy in Locally Advanced Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Society for Radiation
More informationOur Facility. Advanced clinical center with the newest and highly exact technology for treatment of patients with cancer pencil beam
PTC Czech The main goal of radiotherapy is to irreversibly damage tumor cells, whereas the cells of healthy tissue are damaged only reversibly or not at all. Proton therapy currently comes closest to this
More informationProstatectomy, pelvic lymphadenect. Med age 63 years Mean followup 53 months No other cancer related therapy before recurrence. Negative.
Adjuvante und Salvage Radiotherapie Ludwig Plasswilm Klinik für Radio-Onkologie, KSSG CANCER CONTROL WITH RADICAL PROSTATECTOMY ALONE IN 1,000 CONSECUTIVE PATIENTS 1983 1998 Clinical stage T1 and T2 Mean
More informationVan Cutsem E et al. Proc ASCO 2009;Abstract LBA4509.
Efficacy Results from the ToGA Trial: A Phase III Study of Trastuzumab Added to Standard Chemotherapy in First-Line HER2- Positive Advanced Gastric Cancer Van Cutsem E et al. Proc ASCO 2009;Abstract LBA4509.
More informationNew Trends & Current Research in the Treatment of Lung Cancer, Pt. II
New Trends & Current esearch in the Treatment of Lung Cancer, Pt. II Howard (Jack) West, MD President & CEO, GACE Medical Director, Thoracic Oncology Program Swedish Cancer Institute Seattle, WA Cancer
More informationSmall Cell Lung Cancer
Small Cell Lung Cancer Types of Lung Cancer Non-small cell carcinoma (NSCC) (87%) Adenocarcinoma (38%) Squamous cell (20%) Large cell (5%) Small cell carcinoma (13%) Small cell lung cancer is virtually
More informationHow To Treat A Cancer With A Radical
Management of mesothelioma Jan.vanmeerbeeck@ugent.be Amsterdam, March 6, 2010 1 management Palliation Symptomatic care Pain Breathlessness Radiotherapy Chemotherapy Surgery Radical (intention to cure)
More informationRadiation Oncology Nursing Care. Helen Lusby Radiation Oncology Nurse BAROC 2012
Radiation Oncology Nursing Care Helen Lusby Radiation Oncology Nurse BAROC 2012 Definitions Radiation Therapy: Treatment of cancer using x- ray particles that cause ionisation within the cells. External
More information4.8 Lung cancer. 4.8.5 In the UK, three fractionation regimens are most commonly used:
4.8 Lung cancer 4.8.1 In 2005, both NICE (National Institute for Health and Clinical Excellence) and SIGN (Scottish Intercollegiate Guidelines Network) published guidelines on the management of lung cancer.
More informationMETA-ANALYSIS OF CHEMOTHERAPY
MAC-NPC M eta-analysis of Chemotherapy in NasoPharynx Cancer META-ANALYSIS OF CHEMOTHERAPY IN NASO-PHARYNX CARCINOMA An update with trials up to 2010 Initiated by the Institut Gustave Roussy Villejuif,
More informationA new score predicting the survival of patients with spinal cord compression from myeloma
A new score predicting the survival of patients with spinal cord compression from myeloma (1) Sarah Douglas, Department of Radiation Oncology, University of Lubeck, Germany; sarah_douglas@gmx.de (2) Steven
More informationCOMMISSIONING. for ULTRA-RADICAL SURGERY ADVANCED OVARIAN CANCER
COMMISSIONING for ULTRA-RADICAL SURGERY in ADVANCED OVARIAN CANCER WHY THIS MUST HAPPEN PERSPECTIVE COMMISSIONING FOR WHO, FOR WHAT? Biological Basis Surgical Basis International and national standards
More informationLocalised Cancer Treatment. PCI Biotech. Amphinex a new product for localised cancer treatment
Localised Cancer Treatment PCI Biotech Amphinex a new product for localised cancer treatment Disclaimer This document (the Presentation ) has been produced by PCI Biotech Holding ASA (the Company ). The
More informationShould we use Docetaxel in hormone- naïve prostate cancer? Karim Fizazi, MD, PhD Institut Gustave Roussy Villejuif, France
Should we use Docetaxel in hormone- naïve prostate cancer? Karim Fizazi, MD, PhD Institut Gustave Roussy Villejuif, France Disclosure Participation to advisory boards/honorarium from: Amgen, Astellas,
More informationPharmacogenomic markers in EGFR-targeted therapy of lung cancer
Pharmacogenomic markers in EGFR-targeted therapy of lung cancer Rafal Dziadziuszko, MD, PhD University of Colorado Cancer Center, Aurora, CO, USA Medical University of Gdansk, Poland EMEA Workshop on Biomarkers,
More informationHarmesh Naik, MD. Hope Cancer Clinic HOW DO I MANAGE STAGE 4 NSCLC IN 2012: STATE OF THE ART
Harmesh Naik, MD. Hope Cancer Clinic HOW DO I MANAGE STAGE 4 NSCLC IN 2012: STATE OF THE ART Goals Discuss treatment options for stage 4 lung cancer: New and old Discuss new developments in personalized
More informationChapter 7. Accepted for publication in Acta Oncologica
Chapter 7 The potential of intensity-modulated proton radiotherapy to reduce swallowing dysfunction in the treatment of head and neck cancer: a planning comparative study Hans Paul van der Laan, Tara A.
More informationChapter 8. General discussion and conclusions - 153 -
Chapter 8 General discussion and conclusions - 153 - Chapter 8 General discussion and conclusions The aim of this thesis was (1) to investigate if irradiation with scanned intensity-modulated proton therapy
More information2. Background This was the fourth submission for everolimus requesting listing for clear cell renal carcinoma.
PUBLIC SUMMARY DOCUMENT Product: Everolimus, tablets, 5 mg and 10 mg, Afinitor Sponsor: Novartis Pharmaceuticals Australia Pty Ltd Date of PBAC Consideration: November 2011 1. Purpose of Application To
More informationHodgkin Lymphoma Disease Specific Biology and Treatment Options. John Kuruvilla
Hodgkin Lymphoma Disease Specific Biology and Treatment Options John Kuruvilla My Disclaimer This is where I work Objectives Pathobiology what makes HL different Diagnosis Staging Treatment Philosophy
More informationBasic Radiation Therapy Terms
Basic Radiation Therapy Terms accelerated radiation: radiation schedule in which the total dose is given over a shorter period of time. (Compare to hyperfractionated radiation.) adjuvant therapy (add-joo-vunt):
More informationAdjuvant Therapy Non Small Cell Lung Cancer. Sunil Nagpal MD Director, Thoracic Oncology Jan 30, 2015
Adjuvant Therapy Non Small Cell Lung Cancer Sunil Nagpal MD Director, Thoracic Oncology Jan 30, 2015 No Disclosures Number of studies Studies Per Month 12 10 8 6 4 2 0 1 2 3 4 5 6 7 8 9 10 11 12 1 2 3
More informationReport series: General cancer information
Fighting cancer with information Report series: General cancer information Eastern Cancer Registration and Information Centre ECRIC report series: General cancer information Cancer is a general term for
More informationMalignant Mesothelioma State of the Art
Malignant Mesothelioma State of the Art Paul Baas The Netherlands Cancer Institute August 12, 2011, Carlsbad, CA Summary Diagnosis; epithelial type subdivided Pleiomorphic vs other Staging: IASLC-IMIG
More informationStage IIIB disease includes patients with T4 tumors,
Guidelines on Treatment of Stage IIIB Non-small Cell Lung Cancer* James R. Jett, MD, FCCP; Walter J. Scott, MD, FCCP; M. Patricia Rivera MD, FCCP; and William T. Sause, MD, FACR Stage IIIB includes patients
More informationMesothelioma. 1. Introduction. 1.1 General Information and Aetiology
Mesothelioma 1. Introduction 1.1 General Information and Aetiology Mesotheliomas are tumours that arise from the mesothelial cells of the pleura, peritoneum, pericardium or tunica vaginalis [1]. Most are
More informationEvidence tabel Lokaal palliatieve behandelingen
Auteurs, jaartal Mate van bewijs Studie type Follow-up Populatie (incl. steekproef-grootte) Patienten kenmerken Interventie Controle Resultaten Conclusie Opmerkingen, commentaar Hartgrink, 2002 The Netherlands
More informationTransition from 2D to 3D Brachytherapy in Cervical Cancers: The Vienna Experience. Richard Pötter MD. BrachyNext, Miami, 2014.
Transition from 2D to 3D Brachytherapy in Cervical Cancers: The Vienna Experience Richard Pötter MD BrachyNext, Miami, 2014 Disclosures Richard Pötter, MD, does not have any financial relationships or
More informationCase Number: RT2009-114(M) Potential Audiences: Intent Doctor, Oncology Special Nurse, Resident Doctor
Extensive-Stage Small Cell Lung Cancer Post Full-Course Chemotherapy with Residual Locoregional Cancer Disease: the Role and Treatment Consideration of Radiotherapy Case Number: RT2009-114(M) Potential
More informationSur les nouveaux médicaments et les perspectives qu ils offrent (traitement à la carte et survie longue)
Sur les nouveaux médicaments et les perspectives qu ils offrent (traitement à la carte et survie longue) Professeur Jean Trédaniel Unité de cancérologie thoracique Hôpital Saint-Louis Comparison of Four
More informationAdiuwantowe i neoadiuwantowe leczenie chorych na zaawansowanego raka żołądka
Adiuwantowe i neoadiuwantowe leczenie chorych na zaawansowanego raka żołądka Neoadiuvant and adiuvant therapy for advanced gastric cancer Franco Roviello, IT Neoadjuvant and adjuvant therapy for advanced
More informationMesothelioma. Malignant Pleural Mesothelioma
Mesothelioma William G. Richards, PhD Brigham and Women s Hospital Malignant Pleural Mesothelioma 2,000-3,000 cases per year (USA) Increasing incidence Asbestos (50-80%, decreasing) 30-40 year latency
More informationIntegrated Cancer Treatment and Research Centre Wagholi, Pune, INDIA. Recognized as Center of Excellence by Department of AYUSH, Govt.
Integrated Cancer Treatment and Research Centre Wagholi, Pune, INDIA Recognized as Center of Excellence by Department of AYUSH, Govt. of India Supported by Department of Atomic Energy (DAE), Government
More informationProstate Cancer Treatment: What s Best for You?
Prostate Cancer Treatment: What s Best for You? Prostate Cancer: Radiation Therapy Approaches I. Choices There is really a variety of options in prostate cancer management overall and in radiation therapy.
More informationLa Chemioterapia Adiuvante Dose-Dense. Lo studio GIM 2. Alessandra Fabi
La Chemioterapia Adiuvante Dose-Dense Lo studio GIM 2 Alessandra Fabi San Antonio Breast Cancer Symposium -December 10-14, 2013 GIM 2 study Epirubicin and Cyclophosphamide (EC) followed by Paclitaxel (T)
More informationHelical TomoTherapy for Lung Cancer Radiotherapy: Good Science Pays Clinical Dividends Peter Hoban, Ph.D., TomoTherapy Inc.
CLINICAL FEATURE Helical TomoTherapy for Lung Cancer Radiotherapy: Good Science Pays Clinical Dividends Peter Hoban, Ph.D., TomoTherapy Inc. The Challenge Lung cancer kills more people each year in the
More informationAmerican College of Radiology ACR Appropriateness Criteria LOCAL-REGIONAL THERAPY FOR RESECTABLE OROPHARYNGEAL SQUAMOUS CELL CARCINOMAS
Date of origin: 010 American College of Radiology ACR Appropriateness Criteria LOCAL-REGIONAL THERAPY FOR RESECTABLE OROPHARYNGEAL SQUAMOUS CELL CARCINOMAS Expert Panel on Radiation Oncology Head & Neck
More informationRadiotherapy in Lung
Radiotherapy in Lung CancerAnatomy Oblique fissure in both lungs. Horizontal fissure in Right lung. Trachea bifurcates at the level of T5. Lymph nodes are divided into stations. Intrapulmonary, bronchopulmonary
More informationNational Clinical Trials Network Groups Update Fall 2014
National Clinical Trials Network Groups Update Fall 2014 Walter J Curran, Jr, MD An NRG Oncology Group Chair Executive Director Winship Cancer Institute of Emory University Atlanta, GA NCTN Groups Update
More informationClinical Trial Design. Sponsored by Center for Cancer Research National Cancer Institute
Clinical Trial Design Sponsored by Center for Cancer Research National Cancer Institute Overview Clinical research is research conducted on human beings (or on material of human origin such as tissues,
More informationChemotherapy or Not? Anthracycline or Not? Taxane or Not? Does Density Matter? Chemotherapy in Luminal Breast Cancer: Choice of Regimen.
Chemotherapy in Luminal Breast Cancer: Choice of Regimen Andrew D. Seidman, MD Attending Physician Breast Cancer Medicine Service Memorial Sloan Kettering Cancer Center Professor of Medicine Weill Cornell
More informationPrincipal Investigator: Valerie W. Rusch, MD, FACS, Chief, Thoracic Surgery Memorial Sloan-Kettering Cancer Center
Protocol 1101-1088 Phase I study of intra-pleural administration of GL-ONC1 in patients with malignant pleural effusion: primary, metastases and mesothelioma Principal Investigator: Valerie W. Rusch, MD,
More informationIBA Proton Therapy. Biomed days 2015. Vincent Bossier. System Architect Vincent.bossier@iba-group.com. Protect, Enhance and Save Lives
Vincent Bossier System Architect Vincent.bossier@iba-group.com IBA Proton Therapy Biomed days 2015 Protect, Enhance and Save Lives 1 Agenda AN INTRODUCTION TO IBA WHY PROTON THERAPY CLINICAL WORKFLOW TREATMENT
More informationROLE OF RADIATION THERAPY FOR RESECTABLE LUNG CANCER
AFA 08958 From Bench to Bedside From KK DT1 10/27/2015 12:04 PM 01 ROLE OF RADIATION THERAPY FOR RESECTABLE LUNG CANCER Hak Choy, MD University of Texas Southwestern Medical Center Dallas, Texas, USA Orchestrating
More informationCome è cambiata la storia naturale della malattia
Malattia Metastatica del Carcinoma del Grosso Intestino Tecniche e terapie Innovative Come è cambiata la storia naturale della malattia Antonio Frassoldati Oncologia Clinica - Ferrara 29 ottobre 2011 Colorectal
More informationCorso Integrato di Clinica Medica ONCOLOGIA MEDICA AA 2010-2011 LUNG CANCER. VIII. THERAPY. V. SMALL CELL LUNG CANCER Prof.
Corso Integrato di Clinica Medica ONCOLOGIA MEDICA AA 2010-2011 LUNG CANCER. VIII. THERAPY. V. SMALL CELL LUNG CANCER Prof. Alberto Riccardi SMALL CELL LUNG CARCINOMA Summary of treatment approach * limited
More informationLearning about Mouth Cancer
Learning about Mouth Cancer Creation of this material was made possible in part by a pioneering grant from CBCC-USA. Distributed by India Cancer Initiative What is mouth cancer? Our bodies are made up
More informationPathologic Assessment Of The Breast And Axilla After Preoperative Therapy
Pathologic Assessment Of The Breast And Axilla After Preoperative Therapy W. Fraser Symmans, M.D. Associate Professor of Pathology UT M.D. Anderson Cancer Center Pathologic Complete Response (pcr) Proof
More informationPIONEERING BIG DATA IN RADIATION ONCOLOGY
TM PIONEERING BIG DATA IN RADIATION ONCOLOGY Todd McNutt PhD Associate Professor Radiation Oncology Johns Hopkins University Presented at the Target Insight Toronto, CAN May 8 th, 2015 Disclosures This
More informationElderly Cancer - A Comparison Of Two Surgical Identities
Cancer Treatment Reviews xxx (2008) xxx xxx Contents lists available at ScienceDirect Cancer Treatment Reviews journal homepage: www.elsevierhealth.com/journals/ctrv TUMOUR REVIEW Head and neck cancer
More informationWhat is the reference cytotoxic regimen in advanced gastric cancer?
What is the reference cytotoxic regimen in advanced gastric cancer? Florian Lordick Professor of Oncology Director of the University Cancer Center Leipzig (UCCL) Germany What we know from clinical research.
More informationRadiotherapy for Non-Small Cell Lung Cancer. Standard Treatment Options Radiotherapy Planning
Radiotherapy for Non-Small Cell Lung Cancer I II Standard Treatment Options Radiotherapy Planning TNM Staging System Disease Staging - Management is based on disease stage - Stage I-II: early stage - Stage
More informationHealth care and research: Clinical trials in cancer radiotherapy
Health care and research: Clinical trials in cancer radiotherapy Through its health programmes,the IAEA has initiated co-operative clinical studies to improve the outcome in cancer treatment by Jordanka
More informationProstate IMRT: Promises and Problems Chandra Burman, Ph.D. Memorial Sloan-Kettering Cancer Center, New York, NY 10021
Prostate IMRT: Promises and Problems Chandra Burman, Ph.D. Memorial Sloan-Kettering Cancer Center, New York, NY 10021 Introduction Prostate is one of the treatment sites that is well suited for IMRT. For
More informationLung Cancer. Public Outcomes Report. Submitted by Omar A. Majid, MD
Public Outcomes Report Lung Cancer Submitted by Omar A. Majid, MD Lung cancer is the most common cancer-related cause of death among men and women. It has been estimated that there will be 226,1 new cases
More informationLung Cancer Treatment Guidelines
Updated June 2014 Derived and updated by consensus of members of the Providence Thoracic Oncology Program with the aid of evidence-based National Comprehensive Cancer Network (NCCN) national guidelines,
More informationGoals and Objectives: Breast Cancer Service Department of Radiation Oncology
Goals and Objectives: Breast Cancer Service Department of Radiation Oncology The breast cancer service provides training in the diagnosis, management, treatment, and follow-up of breast malignancies, including
More information